Royalty Pharma(US:RPRX) ZACKSยท2025-05-05 14:21Core Viewpoint - Wall Street analysts anticipate Royalty Pharma (RPRX) will report quarterly earnings of $0.99 per share, reflecting a year-over-year increase of 1%, with revenues expected to reach $793.58 million, up 10.7% from the previous year [1] Earnings Estimates - There have been no revisions in the consensus EPS estimate for the quarter over the last 30 days, indicating stability in analysts' forecasts [1] - The consensus estimate for 'Portfolio Receipts- Royalty Receipts- Products- Cystic fibrosis franchise' is projected at $234.18 million, representing a year-over-year change of +7.2% [4] - Analysts predict 'Portfolio Receipts- Royalty Receipts- Products- Tysabri' will reach $58.87 million, indicating a decline of -14.8% year over year [4] - The estimate for 'Portfolio Receipts- Royalty Receipts- Products- Imbruvica' is $45.35 million, reflecting a decrease of -9.4% year over year [5] - The average prediction for 'Portfolio Receipts- Royalty Receipts- Products- Xtandi' is $49.97 million, showing an increase of +21.8% year over year [5] - Analysts expect 'Portfolio Receipts- Royalty Receipts- Products- Promacta' to reach $34.38 million, indicating a decline of -19.2% from the prior year [6] - The estimate for 'Portfolio Receipts- Royalty Receipts- Products- Tremfya' is $38.91 million, reflecting an increase of +7.6% year over year [6] - The consensus for 'Portfolio Receipts- Royalty Receipts- Products- Cabometyx/Cometriq' is $21.62 million, indicating a year-over-year increase of +21.3% [7] - Analysts project 'Portfolio Receipts- Royalty Receipts- Products- Evrysdi' to be $51.98 million, reflecting a change of +15.6% from the prior year [7] - The estimate for 'Portfolio Receipts- Royalty Receipts- Products- Trodelvy' is $11.32 million, indicating a change of +10.2% year over year [8] - The total estimate for 'Portfolio Receipts- Royalty Receipts- Products- Total' is projected at $777.88 million, suggesting a year-over-year increase of +10.4% [8] - Analysts forecast 'Portfolio Receipts- Royalty Receipts- Products- Trelegy' to reach $84.96 million, reflecting a year-over-year change of +20.4% [9] - The estimate for 'Portfolio Receipts- Royalty Receipts- Products- Nurtec ODT/Zavzpret' is projected at $9.01 million, indicating a significant increase of +43.9% year over year [9] Stock Performance - Shares of Royalty Pharma have increased by +5.7% over the past month, outperforming the Zacks S&P 500 composite, which saw a +0.4% change [9]